Received: 28 December 2022
Accepted: 19 January 2023
First Online: 24 January 2023
: The study protocol (version 1.0, Created May 25, 2022) was approved by the Ethics Committee for Clinical Research of Hiroshima University (CRB2022-0004) in August 2022.The principal investigator or co-investigator will obtain written informed consent from all patients who participate in the study after they have been fully informed of the study protocol.This study will be conducted in compliance with the “Declaration of Helsinki” (latest version) of the World Medical Association.To protect the personal information of the participants, the names and medical record numbers of all case report forms and data will be deleted and replaced with descriptions unrelated to the participants, and a correspondence table will be created to anonymize them. Not anonymized documents, such as consent documents, will be stored in a locked cabinet. In addition, the correspondence table will not be provided externally, and information that can identify individuals will not be disclosed in the reports and presentations of the research results.
: Not applicable.
: MK is an inventor of patents owned by the Advanced Telecommunications Research Institute International related to the present work (PCT/JP2014/061544 [WO2014178323] and JP2015-228970/6195329) and patent applications submitted by the Advanced Telecommunications Research Institute International related to the present work (JP2019-034887/6812022, PCT/JP2019/039751 [WO20220075737], and PCT/JP2021/026658 [WO2022014682]). GO and YS are inventors of a patent application submitted by the Advanced Telecommunications Research Institute International related to the present study (PCT/JP2021/026658 [WO2022014682]).Remaining author declare that they have no conflict of interest.Part of the cost of this study will be funded (and provided with research equipment) by XNef, Inc.